Analysts expect over 2018 rising revenue Astrazeneca

Tomorrow the English Astrazeneca will publish its past quarter's figures. Over the current book year the total revenue will be 22,5 billion GBp (consensus estimates). This is slightly more than 2016's revenue of 22,47 billion GBp.

Historical revenues and results Astrazeneca plus estimates 2018

The analysts expect for 2018 a net profit of 4,24 billion GBp. For this year most of the analysts expect a profit per share of 339 GBp. The price/earnings-ratio is then 15,69.

Analysts don't expect the company to pay a dividend. The average dividend yield of the pharmaceutical companies equals a limited 1 percent.

Latest estimates around 6041 GBp

The most recent recommendations for the pharmaceutical company are from Jefferies & Co., Barclays and Sanford C. Bernstein & Co.

Based on the current number of shares Astrazeneca's market capitalization equals 6728,49 billion GBp.

At 11.24 the stock trades 0 percent lower at 5318 GBp.

Historical stock prices Astrazeneca from 2007 till 2018

ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.